763 related articles for article (PubMed ID: 32842547)
1. Endometrial Cancer as a Metabolic Disease with Dysregulated PI3K Signaling: Shedding Light on Novel Therapeutic Strategies.
Kyo S; Nakayama K
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32842547
[TBL] [Abstract][Full Text] [Related]
2. Changes in protein expression due to metformin treatment and hyperinsulinemia in a human endometrial cancer cell line.
Lange C; Machado Weber A; Schmidt R; Schroeder C; Strowitzki T; Germeyer A
PLoS One; 2021; 16(3):e0248103. PubMed ID: 33690729
[TBL] [Abstract][Full Text] [Related]
3. Activation of PI3K/Akt/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer.
Chen J; Zhao KN; Li R; Shao R; Chen C
Curr Med Chem; 2014; 21(26):3070-80. PubMed ID: 24735369
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of midkine by metformin can contribute to its anticancer effects in malignancies: A proposal mechanism of action of metformin in context of endometrial cancer prevention and therapy.
Karadeniz Z; Aynacıoğlu AŞ; Bilir A; Tuna MY
Med Hypotheses; 2020 Jan; 134():109420. PubMed ID: 31634770
[TBL] [Abstract][Full Text] [Related]
5. Investigational PI3K/AKT/mTOR inhibitors in development for endometrial cancer.
Barra F; Evangelisti G; Ferro Desideri L; Di Domenico S; Ferraioli D; Vellone VG; De Cian F; Ferrero S
Expert Opin Investig Drugs; 2019 Feb; 28(2):131-142. PubMed ID: 30574817
[TBL] [Abstract][Full Text] [Related]
6. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
7. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details.
Myers AP
Clin Cancer Res; 2013 Oct; 19(19):5264-74. PubMed ID: 24089439
[TBL] [Abstract][Full Text] [Related]
8. Loss of p27 Associated with Risk for Endometrial Carcinoma Arising in the Setting of Obesity.
McCampbell AS; Mittelstadt ML; Dere R; Kim S; Zhou L; Djordjevic B; Soliman PT; Zhang Q; Wei C; Hursting SD; Lu KH; Broaddus RR; Walker CL
Curr Mol Med; 2016; 16(3):252-65. PubMed ID: 26917264
[TBL] [Abstract][Full Text] [Related]
9. Isoforms S and L of MRPL33 from alternative splicing have isoform‑specific roles in the chemoresponse to epirubicin in gastric cancer cells via the PI3K/AKT signaling pathway.
Li J; Feng D; Gao C; Zhang Y; Xu J; Wu M; Zhan X
Int J Oncol; 2019 May; 54(5):1591-1600. PubMed ID: 30816492
[TBL] [Abstract][Full Text] [Related]
10. Class I Phosphoinositide 3-Kinase
Mazloumi Gavgani F; Smith Arnesen V; Jacobsen RG; Krakstad C; Hoivik EA; Lewis AE
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544563
[TBL] [Abstract][Full Text] [Related]
11. Metformin inhibits proliferation and migration of endometrial cancer cells through regulating PI3K/AKT/MDM2 pathway.
Qiang P; Shao Y; Sun YP; Zhang J; Chen LJ
Eur Rev Med Pharmacol Sci; 2019 Feb; 23(4):1778-1785. PubMed ID: 30840303
[TBL] [Abstract][Full Text] [Related]
12. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
13. [Molecular action of insulin-sensitizing agents].
Kacalska O; Krzyczkowska-Sendrakowska M; Milewicz T; Zabińska-Popiela M; Bereza T; Krzysiek-Maczka G; Krzysiek J
Endokrynol Pol; 2005; 56(3):308-13. PubMed ID: 16350724
[TBL] [Abstract][Full Text] [Related]
14. NLRC5 promotes cell migration and invasion by activating the PI3K/AKT signaling pathway in endometrial cancer.
Fan Y; Dong Z; Shi Y; Sun S; Wei B; Zhan L
J Int Med Res; 2020 May; 48(5):300060520925352. PubMed ID: 32431202
[TBL] [Abstract][Full Text] [Related]
15. [Activation and significance of the PI3K/Akt pathway in endometrium with polycystic ovary syndrome patients].
Zhang HY; Zhang YF; Han YK; Xue FX; Zhao XH; Zhang XL
Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):19-23. PubMed ID: 22455688
[TBL] [Abstract][Full Text] [Related]
16. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
Højlund K
Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
[TBL] [Abstract][Full Text] [Related]
17. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer.
Slomovitz BM; Coleman RL
Clin Cancer Res; 2012 Nov; 18(21):5856-64. PubMed ID: 23082003
[TBL] [Abstract][Full Text] [Related]
18. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase I Trials: Incidence, Predictive Factors, and Management.
Khan KH; Wong M; Rihawi K; Bodla S; Morganstein D; Banerji U; Molife LR
Oncologist; 2016 Jul; 21(7):855-60. PubMed ID: 27151652
[TBL] [Abstract][Full Text] [Related]
19. Estrogen induces endometrial cancer cell proliferation and invasion by regulating the fat mass and obesity-associated gene via PI3K/AKT and MAPK signaling pathways.
Zhang Z; Zhou D; Lai Y; Liu Y; Tao X; Wang Q; Zhao G; Gu H; Liao H; Zhu Y; Xi X; Feng Y
Cancer Lett; 2012 Jun; 319(1):89-97. PubMed ID: 22222214
[TBL] [Abstract][Full Text] [Related]
20. Diabetes mellitus and endometrial carcinoma: Risk factors and etiological links.
Wang Y; Zeng X; Tan J; Xu Y; Yi C
Medicine (Baltimore); 2022 Aug; 101(34):e30299. PubMed ID: 36042597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
